FDA approves Opdivo, Yervoy combination for kidney cancer | RSS News Feed

FDA approves Opdivo, Yervoy combination for kidney cancer - Latest News

RSS Feed for this news: FDA approves Opdivo, Yervoy combination for kidney cancer

FDA approves Opdivo, Yervoy combination for kidney cancer

April 17 (UPI) --The Food and Drug Administration has approved a combination of two immunotherapy drugs, ipilimumab and nivolumab, to treat metastatic kidney cancer. The FDA approved the injection combination Monday based on the CheckMate 214 trial. read more

FDA OKs Bristol-Myers' Opdivo + Yervoy for first-line kidney cancer

The FDA approves Bristol-Myers Squibb's (BMY-8.4%) combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC). The data supporting the indication ... read more

FDA approves Opdivo-Yervoy combination for renal cell carcinoma

The FDA ... cancer patients with medicines that have the potential to extend their lives. As the first treatment option to increase OS for subgroups of patients with advanced renal cell carcinoma compared to sunitinib, the Opdivo plus low-dose Yervoy ... read more

Looking for another news?


FDA Approves Immunotherapy Duo for Kidney Cancer

The Food and Drug Administration (FDA ... either Yervoy plus Opdivo or Sutent (sunitinib). The combination decreased the risk of death by 32 percent compared to Sutent. “This is a major milestone for patients battling advanced kidney cancer. read more

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

The combination of Opdivo and Yervoy lies at the heart of much of Bristol-Myers Squibb’s ambition in immuno-oncology, and an FDA approval for the pairing in kidney cancer is a boost for the company. The US regulator has given the green light to PD-1 ... read more

FDA Approves Combo Tx for Intermediate, Poor-Risk Advanced Kidney Cancer

The Food and Drug Administration (FDA) has approved nivolumab (Opdivo; Bristol-Myers Squibb) and ipilimumab (Yervoy; Bristol-Myers Squibb) as combination therapy for ... and metastatic non-small cell lung cancer (NSCLC). Yervoy, a cytotoxic T-lymphocyte ... read more

BMS' Opdivo, Yervoy combo approved for first-line kidney cancer

Bristol-Myers Squibb's Opdivo, or nivolumab, in combination with Yervoy, or ipilimumab, was approved by the FDA as a treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma in a first-line setting. The decision was backed by ... read more

Bristol-Myers' Opdivo-Yervoy duo snares a quick FDA nod in first-line kidney cancer

It’s been a strange road for Bristol-Myers Squibb’s Opdivo-Yervoy combo in first-line kidney cancer, but the New Jersey drugmaker now has the go-ahead it’s been chasing. The FDA approved the regimen Monday based on data from the phase 3 CheckMate-214 ... read more

FDA Approves Opdivo-Yervoy Combo for Advanced Kidney Cancer

The U.S. Food and Drug Administration has approved a combination ... regimen of Opdivo (3 mg/kg) plus Yervoy (1 mg/kg) the first immuno-oncology combo treatment for intermediate- and poor-risk patients with the kidney cancer in the U.S. BMS is seeking ... read more


FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us